Kuros Biosciences Ag Stock Key Fundamental Indicators
| KURN Stock | CHF 25.24 0.24 0.96% |
As of the 14th of February 2026, Kuros Biosciences secures the Risk Adjusted Performance of (0.02), standard deviation of 2.65, and Mean Deviation of 1.91. Kuros Biosciences AG technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kuros Biosciences mean deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if Kuros Biosciences AG is priced some-what accurately, providing market reflects its recent price of 25.24 per share.
Kuros Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kuros Biosciences' valuation are provided below:Kuros Biosciences AG does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Kuros |
Kuros Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kuros Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kuros Biosciences.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Kuros Biosciences on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Kuros Biosciences AG or generate 0.0% return on investment in Kuros Biosciences over 90 days. Kuros Biosciences is related to or competes with Idorsia, SKAN Group, COSMO Pharmaceuticals, Aevis Victoria, Basilea Pharmaceutica, Medartis Holding, and PolyPeptide Group. Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of bioph... More
Kuros Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kuros Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kuros Biosciences AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 14.6 | |||
| Value At Risk | (4.78) | |||
| Potential Upside | 5.47 |
Kuros Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kuros Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kuros Biosciences' standard deviation. In reality, there are many statistical measures that can use Kuros Biosciences historical prices to predict the future Kuros Biosciences' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.29) | |||
| Treynor Ratio | (1.31) |
Kuros Biosciences February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (1.30) | |||
| Mean Deviation | 1.91 | |||
| Coefficient Of Variation | (3,267) | |||
| Standard Deviation | 2.65 | |||
| Variance | 7.03 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.29) | |||
| Treynor Ratio | (1.31) | |||
| Maximum Drawdown | 14.6 | |||
| Value At Risk | (4.78) | |||
| Potential Upside | 5.47 | |||
| Skewness | 0.6207 | |||
| Kurtosis | 1.5 |
Kuros Biosciences Backtested Returns
Kuros Biosciences has Sharpe Ratio of -0.0306, which conveys that the firm had a -0.0306 % return per unit of risk over the last 3 months. Kuros Biosciences exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kuros Biosciences' Mean Deviation of 1.91, risk adjusted performance of (0.02), and Standard Deviation of 2.65 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.0697, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kuros Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kuros Biosciences is expected to be smaller as well. At this point, Kuros Biosciences has a negative expected return of -0.0812%. Please make sure to verify Kuros Biosciences' maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Kuros Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.48 |
Average predictability
Kuros Biosciences AG has average predictability. Overlapping area represents the amount of predictability between Kuros Biosciences time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kuros Biosciences price movement. The serial correlation of 0.48 indicates that about 48.0% of current Kuros Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.48 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 1.02 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Kuros Biosciences AG has a Return On Asset of 0.0257. This is 100.29% lower than that of the Health Care Equipment & Supplies sector and 100.11% lower than that of the Health Care industry. The return on asset for all Switzerland stocks is 118.36% lower than that of the firm.
Kuros Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kuros Biosciences's current stock value. Our valuation model uses many indicators to compare Kuros Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kuros Biosciences competition to find correlations between indicators driving Kuros Biosciences's intrinsic value. More Info.Kuros Biosciences AG is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kuros Biosciences' earnings, one of the primary drivers of an investment's value.Kuros Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kuros Biosciences' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kuros Biosciences could also be used in its relative valuation, which is a method of valuing Kuros Biosciences by comparing valuation metrics of similar companies.Kuros Biosciences is currently under evaluation in return on asset category among its peers.
Kuros Fundamentals
| Return On Equity | -0.0862 | ||||
| Return On Asset | 0.0257 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 963.28 M | ||||
| Shares Outstanding | 39.18 M | ||||
| Shares Owned By Insiders | 27.83 % | ||||
| Shares Owned By Institutions | 23.40 % | ||||
| Price To Book | 12.78 X | ||||
| Price To Sales | 9.51 X | ||||
| Revenue | 75.56 M | ||||
| Gross Profit | 91.68 M | ||||
| EBITDA | (561 K) | ||||
| Net Income | (3.92 M) | ||||
| Cash And Equivalents | 18.33 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.79 M | ||||
| Current Ratio | 4.91 X | ||||
| Book Value Per Share | 1.90 X | ||||
| Cash Flow From Operations | 3.14 M | ||||
| Earnings Per Share | (0.15) X | ||||
| Target Price | 34.65 | ||||
| Number Of Employees | 158 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 983.3 M | ||||
| Total Asset | 84.54 M | ||||
| Retained Earnings | (45.43 M) | ||||
| Working Capital | 23.86 M | ||||
| Net Asset | 84.54 M |
About Kuros Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kuros Biosciences AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kuros Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kuros Biosciences AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland. Kuros N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 35 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kuros Stock Analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.